Giordano A, Xu B, Yoshinami T, Huang CS, et al. Atirmociclib and fulvestrant for patients with HR+/HER2- advanced/metastatic breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor: primary analysis of the randomized FourLight-1 trial. Ann Oncol 2026 Oct 24:S0923-7534(26)08074-9. doi: 10.1016/j.annonc.2026.10.1282.
PMID: 42926110